Literature DB >> 11524097

The development of the Chemotherapy Symptom Assessment Scale (C-SAS): a scale for the routine clinical assessment of the symptom experiences of patients receiving cytotoxic chemotherapy.

V Brown1, J Sitzia, A Richardson, J Hughes, H Hannon, C Oakley.   

Abstract

The management of symptoms experienced by patients receiving cytotoxic chemotherapy influences quality of life during treatment. Symptom management may be improved through a structured approach to symptom assessment. This paper describes the development of the Chemotherapy Symptom Assessment Scale (C-SAS), a 24-item scale designed for the routine assessment of symptoms experienced by patients receiving cytotoxic chemotherapy. The scale development process focused both upon the psychometric properties and the clinical usefulness of the scale. Patients and health professionals played a significant role in item selection and scale design in order to maximise the clinical utility of the C-SAS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524097     DOI: 10.1016/s0020-7489(00)00106-1

Source DB:  PubMed          Journal:  Int J Nurs Stud        ISSN: 0020-7489            Impact factor:   5.837


  9 in total

1.  Effect on Symptom Management Education Receiving Patients of Chemotherapy.

Authors:  Zümrüt Akgün Şahin; Seher Ergüney
Journal:  J Cancer Educ       Date:  2016-03       Impact factor: 2.037

2.  Effectiveness of Internet-based interventions in managing chemotherapy-related symptoms in patients with cancer: a systematic literature review.

Authors:  S Moradian; N Voelker; C Brown; G Liu; D Howell
Journal:  Support Care Cancer       Date:  2017-09-25       Impact factor: 3.603

Review 3.  The psychometric properties of cancer multisymptom assessment instruments: a clinical review.

Authors:  Aynur Aktas; Declan Walsh; Jordanka Kirkova
Journal:  Support Care Cancer       Date:  2015-04-19       Impact factor: 3.603

4.  Evaluation of the Efficacy of the Three-Component Health Care Management Program HEWCOT in Colorectal Cancer Patients Receiving Chemotherapy.

Authors:  Iknur Aydin Avci; Birsen Altay; Figen Cavusoglu; Ayse Cal; Nuran Mumcu; Dilek Celik Eren; Ozge Oz; Alaattin Altin; Ozden Karaoglanoglu; Ayse Buberci
Journal:  J Cancer Educ       Date:  2020-04       Impact factor: 2.037

5.  Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity.

Authors:  N Kearney; L McCann; J Norrie; L Taylor; P Gray; M McGee-Lennon; M Sage; M Miller; R Maguire
Journal:  Support Care Cancer       Date:  2008-10-25       Impact factor: 3.603

6.  Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire.

Authors:  Sieta T de Vries; Peter G M Mol; Dick de Zeeuw; Flora M Haaijer-Ruskamp; Petra Denig
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

7.  Utilising handheld computers to monitor and support patients receiving chemotherapy: results of a UK-based feasibility study.

Authors:  N Kearney; L Kidd; M Miller; M Sage; J Khorrami; M McGee; J Cassidy; K Niven; P Gray
Journal:  Support Care Cancer       Date:  2006-03-09       Impact factor: 3.603

8.  The Patient Remote Intervention and Symptom Management System (PRISMS) - a Telehealth- mediated intervention enabling real-time monitoring of chemotherapy side-effects in patients with haematological malignancies: study protocol for a randomised controlled trial.

Authors:  Sibilah Breen; David Ritchie; Penelope Schofield; Ya-Seng Hsueh; Karla Gough; Nick Santamaria; Rose Kamateros; Roma Maguire; Nora Kearney; Sanchia Aranda
Journal:  Trials       Date:  2015-10-19       Impact factor: 2.279

9.  The eSMART study protocol: a randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (ASyMS) remote technology for patients with cancer.

Authors:  Roma Maguire; Patricia A Fox; Lisa McCann; Christine Miaskowski; Grigorios Kotronoulas; Morven Miller; Eileen Furlong; Emma Ream; Jo Armes; Elisabeth Patiraki; Alexander Gaiger; Geir V Berg; Adrian Flowerday; Peter Donnan; Paul McCrone; Kathi Apostolidis; Jenny Harris; Stylianos Katsaragakis; Alison R Buick; Nora Kearney
Journal:  BMJ Open       Date:  2017-06-06       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.